Even though the idea of starting economic evaluations early in the product life cycle of medical technologies has gained popularity in the past few years, its use has not been fully exploited yet. In this thesis, we aimed to contribute to the literature on early cost-effectiveness analysis (CEA), value of information analysis and resource modeling analysis, particularly applied to medical technologies for emerging breast cancer interventions. After a short introduction (chapter 1), this thesis is divided in three parts, distinguished by the type of technologies assessed: The first part focuses on predictive biomarkers to personalize systemic treatment (chapters 2, 3, 4), the second part focuses on imaging techniques to guide the personalization of neoadjuvant chemotherapy (NACT) (chapters 5, 6, 7), and the third part focuses on imaging as a tool to detect distant metastases (chapter 8).
|Award date||1 Apr 2016|
|Place of Publication||Enschede|
|Publication status||Published - 1 Apr 2016|